Survival outcomes and influencing factors in Zhengzhou HIV/AIDS patients following antiretroviral therapy initiation (2014-2024): a retrospective cohort analysis
From 2014 to 2024, the overall survival of HIV-infected individuals receiving antiviral therapy in Zhengzhou was favorable. However, advanced age and a low baseline CD4<sup>+</sup> T lymphocyte count were identified as significant factors for an elevated mortality risk. It is recommended to enhance clinical management for older patients and to initiate treatment early to improve CD4<sup>+</sup> T lymphocyte levels, thereby further improving survival outcomes.
Authors
- Xuan Yang
- Zhihui Zhang
- Zhaoyun Chen
- Yan Sun
- Meng Deng
- Qiong Li
Institutions
- Fairfield Infectious Diseases Hospital (AU)
- Office of Infectious Diseases (US)
- Infectious Clinical Hospital No. 1 (RU)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2026-03-11
- DOI
- https://doi.org/10.3389/fpubh.2026.1733724
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00